EMA Authorised: Rivaroxaban Accord (rivaroxaban) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Accord Healthcare's rivaroxaban product (Rivaroxaban Accord) for multiple indications including acute coronary syndrome, coronary artery dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Coronary Artery Disease
• Coronary Syndrome
• Peripheral Arterial Disease
• Pulmonary Embolism
• Stroke
• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban Accord (rivaroxaban)

Snippet

Status: Authorised. Therapeutic area: Acute Coronary Syndrome;Coronary Artery Disease;Peripheral Arterial Disease;Venous Thromboembolism;Stroke;Atrial Fibrillation;Pulmonary Embolism. MAH: Accord Healthcare S.L.U.. Decision date: 27/09/2023